Arm CEO: AI Will Cure Cancer, But Chip Shortages Slow Progress

Artificial intelligence will eventually discover a cure for cancer that remains beyond the reach of human researchers, according to the head of the UK's largest tech firm. Rene Haas, CEO of Arm Holdings, believes this breakthrough will occur within our lifetime, though he warns that current hardware limitations are stalling the pace of discovery.

Speaking to the BBC, Haas explained that the complexity of modeling human cells and the specific ways DNA markers are impacted by cancer is currently too great for both human scientists and existing computers. While AI is the key to solving these problems, Haas noted that the rapid expansion of the technology is being hindered by a critical shortage of the semiconductor chips required to build and power the necessary data centers.

The Infrastructure Bottleneck

This tension between algorithmic potential and physical reality comes as Arm finds itself at the center of a global AI boom. The company, which designs CPUs used in hundreds of billions of devices including smartphones, cars, and smartwatches, saw its valuation soar during the recent tech surge. At its peak share price, Arm became the most valuable UK-based company in history in cash terms.

Haas brings a rare intersection of expertise to this discussion, having served on the board of pharmaceutical giant AstraZeneca until April. His perspective bridges the gap between the silicon required for computation and the biological complexity of oncology, highlighting that the path to a cure is as much a supply chain issue as it is a scientific one.

Strategic Implications for Healthcare

The dependency on semiconductor availability underscores a strategic shift in medical innovation. The transition of AI from a generative tool—capable of writing text or creating images—to a life-saving medical instrument depends entirely on the physical infrastructure of the global supply chain. Without a steady increase in chip production and data center capacity, the ability to model the human body at a granular level remains theoretical.

The Road Ahead

Beyond medicine, Haas anticipates that the current AI trajectory will lead to the widespread adoption of humanoid robots within the next five years. However, the immediate priority for the industry remains the scaling of hardware. The global tech community must now navigate the pressure on semiconductor supply chains to ensure that the computing power required for the next generation of medical breakthroughs is actually available.